Shenzhen Osa Pharmaceutical Co., Ltd.

Primary objective: To evaluate the bioequivalence of the test formulation (Apixaban tablets, Shenzhen Osa Pharmaceutical Co., Ltd., 2.5 mg) and the reference formulation (Eliquis®, Bristol-Myers Squibb Co Pharmaceutical Research Institude, 2.5 mg) after single oral administration on an empty stomach and after meals in healthy subjects. Secondary objective: To observe the safety of the test formulation (Apixaban tablets, 2.5 mg) and the reference formulation (Apixaban tablets, 2.5 mg, trade name: Eliquis®) in healthy subjects.

Primary study objective: To evaluate the bioequivalence of the test preparation (atorvastatin calcium tablets, Shenzhen Osa Pharmaceutical Co., Ltd., 10 mg) and the reference preparation (Lipitor®, Pfizer Pharmaceutical Co., Ltd., 10 mg) after single oral administration on an empty stomach and after meals in healthy subjects. Secondary study objective: To observe the safety of the test preparation atorvastatin calcium tablets (10 mg) and the reference preparation atorvastatin calcium tablets (10 mg, trade name: Lipitor®) in healthy subjects.

1. Main research purpose Among hypertensive participants with MTHFR 677 TT genotype, compare whether there is a significant difference in the efficacy of amlodipine folic acid tablets (group B+C) and amlodipine tablets (group A) in preventing first ischemic stroke. 2. Secondary research purpose (1) Among the above-mentioned hypertensive participants, compare whether there is a significant difference in the efficacy of preventing first ischemic stroke between group B vs. group A, group C vs. group A, and group B vs. group C. (2) Among the above-mentioned hypertensive participants, compare group B+C vs. group A, group B vs. group A, group C vs. group A, group B vs. group C in preventing first stroke and cardiovascular and cerebrovascular composite endpoints. , whether there is a significant difference in the efficacy of renal endpoints. (3) In the above-mentioned hypertensive participants, compare group B+C vs. group A in preventing first hemorrhagic stroke. Is there a significant difference in the efficacy of first myocardial infarction, first coronary revascularization, and cardiovascular and cerebrovascular death? 3. Other research purposes (1) Among the above-mentioned hypertensive participants, compare whether there is a significant difference in the efficacy of preventing malignant tumors and all-cause death between group B+C and group A. (2) Among the above-mentioned hypertensive participants, compare the preventive blood pressure levels, variability and blood pressure reduction standards of group B+C vs. group A, group B vs. group A, group C vs. group A, group B vs. group C. rate, serum folate levels and changes, and plasma total homocysteine levels and changes.